Patent EP-4144864-A1 (EP)
Inventor: GHO CONRADUS GHOSAL
IPC: C12Q1/6883
Filed: 2021-09-06
Abstract: An  in vitro  method for diagnosis of occurrence and/or assessing severity of ischemic vascular disease (IVD) and/or ischemic vascular disease-related complication (IVDC) in a female subject, said method comprising the steps of a. determining a first expression level of each RNA biomarker from the group comprising ADAMTS8, AK094845, AMOT, BTRC, CCDC57, CNTNAP3, COL2A1, DCHS2, DENND5B, FOXN4, GTF2IRD1, HNRNPR, KIF18B, LPAR6, NBLA00301, NKAIN3, NRXN2, MMP11, PRSS33, PTS, QTRTD1, STK36, TBCB, TCONS_00015170-XLOC_007214, TDG and UROC1, in CD45+ mononuclear cells (MNC) from a test sample collected from said female subject, and b. comparing said first expression level of each RNA biomarker from the group comprising ADAMTS8, AK094845, AMOT, BTRC, CCDC57, CNTNAP3, COL2A1, DCHS2, DENND5B, FOXN4, GTF2IRD1, HNRNPR, KIF18B, LPAR6, NBLA00301, NKAIN3, NRXN2, MMP11, PRSS33, PTS, QTRTD1, STK36, TBCB, TCONS_00015170-XLOC_007214, TDG and UROC1, in CD45+ mononuclear cells (MNC) collected from said female subject with a control expression level of each RNA biomarker from the group comprising ADAMTS8, AK094845, AMOT, BTRC, CCDC57, CNTNAP3, COL2A1, DCHS2, DENND5B, FOXN4, GTF2IRD1, HNRNPR, KIF18B, LPAR6, NBLA00301, NKAIN3, NRXN2, MMP11, PRSS33, PTS, QTRTD1, STK36, TBCB, TCONS_00015170-XLOC_007214, TDG and UROC1 from a control sample collected from control female subject(s), c. diagnosing occurrence and/or assessing severity of IVD and/or IVDC based on the differences between the first expression level and the control expression level, wherein it is determined that IVD and/or IVDC occurred or is severe if at least two, preferably at least five, preferably at least ten, more preferably at least fourteen, RNA biomarkers from said group are different between the first expression level and the control expression level. An  in vitro  method for diagnosis of occurrence and/or assessing severity of ischemic vascular disease (IVD) and/or ischemic vascular disease-related complication (IVDC) in a male subject, said method comprising the steps of a. determining a first expression level of each RNA biomarker from the group comprising ENST00000440123, TCONS_00025321-XLOC_012127, MTPAP, ENST00000430988 , USP12-AS1, ProbSetID_17118935, TRH, XR_109422 // LOC100507049, ENST00000456944, TBX5 , TCONS_I2_00026656-XLOC_I2_013873, ExonID_5262586, RGL3, MFSD2B, CALD1, ENST00000518932, TOM1L2, LAMA4, COQ6, SALL4, CABLES1, POLRMT, SLC23A1, TREML2, SNHG15, CYP51A1, ExonID_5299845 and TCONS_00017554-XLOC_008249, in CD45+ mononuclear cells (MNC) from a test sample collected from said male subject, and b. comparing said first expression level of each RNA biomarker from the group comprising ENST00000440123, TCONS_00025321-XLOC_012127, MTPAP, ENST00000430988 , USP12-AS1, ProbSetID_17118935, TRH, XR_109422 // LOC100507049, ENST00000456944, TBX5 , TCONS_I2_00026656-XLOC_I2_013873, ExonID_5262586, RGL3, MFSD2B, CALD1, ENST00000518932, TOM1L2, LAMA4, COQ6, SALL4, CABLES1, POLRMT, SLC23A1, TREML2, SNHG15, CYP51A1, ExonID_5299845 and TCONS_00017554-XLOC_008249, in CD45+ mononuclear cells (MNC) collected from said male subject with a control expression level of each RNA biomarker from the group comprising ENST00000440123, TCONS_00025321-XLOC_012127, MTPAP, ENST00000430988 , USP12-AS1, ProbSetID_17118935, TRH, XR_109422 // LOC100507049, ENST00000456944, TBX5 , TCONS_I2_00026656-XLOC_I2_013873, ExonID_5262586, RGL3, MFSD2B, CALD1, ENST00000518932, TOM1L2, LAMA4, COQ6, SALL4, CABLES1, POLRMT, SLC23A1, TREML2, SNHG15, CYP51A1, ExonID_5299845 and TCONS_00017554-XLOC_008249 from a control sample collected from control male subject(s), c. diagnosing occurrence and/or assessing severity of IVD and/or IVDC based on the differences between the first expression level and the control expression level, wherein it is determined that IVD and/or IVDC occurred or is severe if at least two, preferably at least ten, more preferably at least fourteen, more preferably at least sixteen, more preferably at least eighteen, RNA biomarkers from said group are different between the first expression level and the control expression level.